Career Development Award
|
| |||||||
|
Posted By: Joynita Willis on 04/27/2023 | ||||||||
|
The National Hemophilia Foundation (NHF), a nonprofit organization founded in 1948, is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy, and research. NHF seeks research grant applications from established investigators, preferably at the assistant professor level or above, who have demonstrated a commitment to bleeding disorders research. We especially encourage innovative projects that promote the development of novel technologies and/or therapies to advance the field of bleeding disorders research.
Eligibility Requirements Career Development Award (CDA) candidates must hold a MD, PhD, or equivalent degree, with no more than six years of postdoctoral years of experience in hematology, nor more than six years since completion of medical training. United States citizenship is not required; however, applicants must be affiliated with or be faculty members of a U.S.-based domestic organization such as - universities, colleges, hospitals, or laboratories. Only non-commercial institutions and investigators associated with a non-commercial institution are eligible to apply for this award. The CDA award recipient will be expected to spend at least 75% of their working time on the funded research project. The CDA recipient and his/her mentor are also expected to remain at their institution for the duration of the project. For the application, letters of support from appropriate institutional officials (department chair and financial grants officer) indicating the institution’s commitment to allow the candidate to focus his/her efforts on the stated research project will be required. Funding NHF will award up to $70,000 annually for a maximum of three years. Scope of Research NHF is interested in funding innovative research studies in bleeding disorders to be carried out at the sub cellular, cellular, animal, or human/patient levels. While gene therapy has been an approach which has shown much promise in hemophilia, no one method has been demonstrated to be superior. Multiple experimental strategies may be undertaken to help find a “cure” for bleeding disorders. NHF is seeking research proposals on the nature, propagation, and use of hematopoietic, liver, or stem cells as an approach for gene transfer in hemophilia or for other novel approaches for treating bleeding disorders. Studies to evaluate the genetic and immunologic bases for inhibitor development may lead to strategies to circumvent this potential complication of clotting factor replacement and/or gene transfer. This research could provide the opportunity to determine the prognostic indicators that place patients at risk of inhibitor development. Inhibitor research may also lead to the development of synthetic replacement factor and gene therapy products with decreased immunogenicity. This includes research on genotype/phenotype relationships and susceptibility to inhibitors. Structural studies of clotting factor proteins are needed to design more efficacious, longer-lived clotting factor proteins. Development of both small, biologically active, orally delivered molecules and improved protein delivery systems represent strategies that could lead to advances in our understanding of bleeding disorders. Better functional assays for clotting factor proteins are also needed. Reproducible, low-volume measure of factor VIII and factor IX activity in different animal models would greatly facilitate validation of in vivo gene therapy studies as well as innovative alternative treatment strategies. All CDA research proposals are subjected to a rigorous peer review process. Applications will be reviewed on scientific merit and scored in terms of project significance, scientific approach, innovation, investigator qualifications and institutional environment. Deadlines All interested candidates need to request a ‘Letter of Intent’ (LOI) Intake form by email to Joie Willis, Research Grants Administrator, at jwillis@hemophilia.org by no later than May 15, 2023 at 11:59pm Eastern. Requests that do not arrive by the deadline will not be accepted. LOIs along with the NHF Intake Form will not be considered for review unless signed by the candidate. LOIs should be submitted on institutional letterhead and addressed to “Members of NHF’s Research Review Committee,” be 1 to 1.5 pages in length using a basic font of no less than 11 points with 1-inch margins. It ought to include a brief introduction of the candidate/researcher, information about his/her mentor, and a brief description of the proposed research project. Letters must be accompanied by a CV (NIH-style BioSketch preferred) for both the candidate and his/her mentor. LOIs will be evaluated by members of NHF’s Research Review Committee. The committee will collectively decide which candidates will be invited to submit a full application. The selected candidates will have until Friday, June 30, 2023, at 5pm EST to submit their full CDA application to NHF. Applications that do not arrive by the deadline will not be accepted. Inquiries Inquiries for NHF Research Grant & Fellowship Programs, including written request for NHF's Research Grant Policies will be addressed by Samantha Carlson, LMSW, Sr. Manager of Research Programs & Partnerships, at scarlson@hemophilia.org. | |
| Scholarship/Grant Site: https://www.hemophilia.org/research/fund-your-research/career-development-award |
